D&D Pharmatech
Financials
Valuation Metrics
D&D Pharmatech's Market Cap is ₩2.1T. At end of 2025 it was ₩4.2T. Ranked #211 of 2,419 in KR market (top 9%), #44 of 1,638 on KOSDAQ (top 3%), #19 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 8%) by Market Cap.
Investment Metrics(as of 2026-10-07)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 2.12T KRW | KR#211/2,419 Sec#19/231 |
| Revenue | 2.75B KRW | KR#2,373/2,419 Sec#209/231 |
| Net Income | -21.75B KRW | KR—/2,419 Sec—/231 |
| Total Assets | 97.54B KRW | KR#1,805/2,419 Sec#141/231 |
| Net Assets | 78.98B KRW | KR#1,599/2,419 Sec#129/231 |
| Employees | 24 | KR#2,230/2,419 Sec#209/231 |
| Value | ||
| P/B | 26.88x | KR#2,405/2,419 Sec#227/231 |
| P/S | 771.78x | KR#2,409/2,419 Sec#226/231 |
| FCF Yield | -1.00% | KR—/2,419 Sec—/231 |
| Profitability | ||
| ROE | -27.54% | KR#2,157/2,419 Sec#169/231 |
| ROA | -22.30% | KR#2,263/2,419 Sec#183/231 |
| Op. Margin | -1367.89% | KR#2,381/2,419 Sec#217/231 |
| Revenue Growth | -62.42% | KR#2,310/2,419 Sec#208/231 |
| Financial Health | ||
| Debt Ratio | 23.50% | KR#453/2,419 Sec#53/231 |
| Total Debt | 2.54B KRW | KR#1,883/2,419 Sec#183/231 |
| FCF | -21.20B KRW | KR#1,906/2,419 Sec#182/231 |
| Cash | 32.88B KRW | KR#951/2,419 Sec#63/231 |
| Performance | ||
| 1Y Return | -8.02% | KR#1,001/2,419 Sec#63/231 |
| 1M Return | -7.14% | KR#1,949/2,419 Sec#190/231 |
| From 52W High | -60.42% | KR#1,913/2,419 Sec#160/231 |
| 1Y MDD | -62.45% | KR#1,621/2,419 Sec#133/231 |
| Trading | ||
| Volume | 697,691 shares | KR#166/2,419 Sec#27/231 |
| Trading Value | 32.35B KRW | KR#121/2,419 Sec#9/231 |
| Foreign Own. | 10.20% | KR#471/2,419 Sec#39/231 |
| Per Share | ||
| EPS | -473 KRW | KR—/2,419 Sec—/231 |
| BPS | 1,717 KRW | KR#2,146/2,419 Sec#179/231 |
Company Info
D&D Pharmatech, established in 2014 and listed on KOSDAQ in 2024, holds subsidiaries such as Neuraly Inc., Valted Seq Inc., and P4 Microbiome Inc. The company researches and develops new drugs for metabolic, neurodegenerative, and fibrotic diseases using technologies like GLP-1, with a diverse pipeline including oral obesity treatments. Leveraging new drug development capabilities through drug delivery technology, it advances its business via technology transfer and co-development with global partners. D&D Pharmatech is headquartered in Seongnam-si, Gyeonggi-do.